Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

ts.

Discovery's lead product candidate, Surfaxin(r), is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. Surfaxin is also being developed for other neonatal and pediatric indications. Aerosurf(tm), Discovery's aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect Discovery's actual results and could cause results to differ from those contained in these forward-looking statements are the risk that Discovery may not profitably develop and market its products, the risk that financial market conditions may change, the risk that Discovery will not be able to raise additional capital or enter into additional collaboration agreements, the risk that Discovery will not be able to attract or retain qualified personnel or timely provide for a successful sales and marketing organization, risks relating to the progress of Discovery's research and development,, risks in the FDA or other regulatory agency review process generally, including that such regulatory authority will not approve the marketing and sale of a drug product even after acceptance of an application or that approval by such regulatory agency may be withheld, delayed and/or limited by indications or other label limita
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical ... CMED ), a leading China-based ... its unaudited financial results for the ... 2011 ("1Q FY2011") today.1 Q ...
... More than a decade of targeted Muscular Dystrophy Association-funded ... support of the MDA Labor Day Telethon and thousands ... providing financial assistance for the start of the first ... pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, ...
Cached Medicine Technology:China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 2MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 3MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy 4
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/23/2014)... Methylphenidate, also known as Ritalin, may prevent the depletion ... Science , a journal of the Association for Psychological ... a diet or trying to focus attention on a ... suggests one potential explanation for this difficulty: Exerting self-control ... to exert self-control effectively on subsequent tasks. , "It ...
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Society of ... Surgeons Annual Meeting, BALTIMORE, Oct. 28 One facelift or ... In fact,plastic surgeons analyze facial features and configurations to,individualize results based ... at the American Society of Plastic Surgeons (ASPS) Plastic,Surgery 2007 conference ...
... Annual Meeting, BALTIMORE, Oct. 28 While the ... to for fear of sagging,breasts. However, breastfeeding alone has ... first-of-its-kind study presented today at the,American Society of Plastic ... women who come in for breast surgery tell us ...
... in which the bladder forms outside of the abdomen ... with the same condition, according to a small study ... The condition, known as bladder exstrophy, requires a series ... early adolescence.The findings are being reported at the American ...
... 2007 MedImmune, Inc. today announced it will present ... 2007 National Conference & Exhibition, adding to the companys ... syncytial virus (RSV), a leading cause of hospitalization among ... that provide key insights into how we can optimize ...
... connected, study finds , THURSDAY, Oct. 25 (HealthDay ... a follow-up osteoporosis management program that includes electronic ... , Osteoporosis -- which increases the risk of ... 65 and older. Medication can greatly reduce fracture ...
... American Red Cross,Blood Services national system continues to ship ... to help stabilize the blood,supply in the region affected ... provided nearly 2,000 blood products to date,in support of ... drives in southern California have been curtailed due to ...
Cached Medicine News:Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 2Health News:Facelift, Botox, or Both? Depends Upon Your Decade of Life 3Health News:Breastfeeding Does Not Create Sagging Breasts; Study Throws Out Old Wives' Tale 2Health News:MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics 2Health News:Older Women Gain From Good Post-Fracture Care 2Health News:American Red Cross Blood Services Supports Blood Needs of Southern California 2
... Direct to High Res SSP kits provide high resolution ... Locus specific typing on a single tray reduces QC ... from genomic DNA to high resolution results, no need ... with a single tray , Unique reaction pattern for ...
... the storage of blood plasma in full ... attention to operating temperatures and performance means ... Standard freezer you will minimise bag cracking ... temperature an additional benefit is reduced thawing ...
Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost times....
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: